Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Who Took Part

The abstract describes 108 children taking part.

PubMed indexes the participants as children and teenagers, both men and women.

108 and 343 children with treatment-naive GHD from 6 hospitals in China were enrolled in the phase II and III studies respectively.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the children and staff both knew the treatment.

More than one site took part, so the children came from several places.

Phase II and III, multicenter, open-label, randomized controlled trials.

Other growth-related parameters, safety and compliance were also monitored.

What Was Measured

Topics PubMed links to this paper include Dwarfism, Pituitary, Human Growth Hormone, Polyethylene Glycols and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 108 children.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (European journal of endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.